| Expression pattern: |
UP |
| Associated gene: |
CDKL1 |
| Associated microRNA: |
miR-144-5p |
| Biological function: |
circRACGAP1 promotes NSCLC cell proliferation, cell-cycle progression, tumor growth, and Gefitinib resistance; circRACGAP1 knockdown suppresses proliferation, arrests cells at G1 phase, inhibits tumor growth, and enhances sensitivity to Gefitinib. |
| Molecular mechanism: |
circRACGAP1 acts as a sponge for miR-144-5p and regulates the miR-144-5p/CDKL1 pathway, thereby modulating CDKL1-associated cell-cycle proteins and NSCLC proliferation and drug resistance. |
| Biological pathway or process: |
ceRNA regulation (promotes); proliferation (promotes); cell cycle (promotes); apoptosis (inhibits); drug resistance (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; Clinical Sample Validation; Luciferase Reporter Assay; RNA Pull-Down; Transfection; CCK8; EdU Staining; Colony Formation Assay; Cell Cycle Assay; Annexin V/PI Flow Cytometry; Western Blot; In Vivo Animal Model; IHC (Immunohistochemistry); Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circRACGAP1 expression is associated with worse survival in NSCLC patients and circRACGAP1 may be a potential diagnostic and therapeutic target for NSCLC. |
| Description: |
circRACGAP1 is up-regulated in NSCLC tissues and cell lines and high expression is associated with poorer patient survival. Functionally, circRACGAP1 promotes NSCLC proliferation, cell-cycle progression, tumor growth, and Gefitinib resistance. Mechanistically, it acts as a miR-144-5p sponge to regulate CDKL1 signaling. |
| Confidence score: |
0.8466 |